End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) and Ghent University, Jette, Belgium.
Department of Public Health, Interuniversity Center for Health Economic Research (ICHER), Ghent University, Gent, Belgium.
BMJ Open. 2019 Jan 21;9(1):e025180. doi: 10.1136/bmjopen-2018-025180.
To evaluate the impact of palliative home care support on the quality of care and costs in the last 14 days of life.
Matched cohort study using linked administrative databases.
All people who died in Belgium in 2012 (n=107 847).
8837 people who received palliative home care support in the last 720 to 15 days of life matched 1:1 by propensity score to 8837 people who received usual care.
Receiving the allowance for palliative home patients, multidisciplinary palliative home care team visit or palliative nurse or physiotherapist visit at home.
Home death, number of family physician contacts, number of primary caregiver contacts, hospital death, hospital admission, intensive care unit (ICU) admission, emergency department (ED) admission, diagnostic testing, blood transfusion and surgery. Total inpatient and outpatient costs. All outcomes were measured in the last 14 days of life.
In the unmatched cohort, 11 149 (13.5%) people received palliative home care support in the last 720 to 15 days of life. After matching, those using palliative home care support had, compared with those who did not, more family physician contacts (mean 3.1 [SD=6.5] vs 0.8 [SD=1.2]), more chance of home death (56.2%vs13.8%; relative risk [RR]=4.08, 95% CI 3.86 to 4.31), lower risk of hospital admission (27.4%vs60.8%; RR=0.45, 95% CI 0.43 to 0.46), ICU admission (18.3%vs40.4%; RR=0.45, 95% CI 0.43 to 0.48) or ED admission (15.2%vs28.1%; RR=0.54, 95% CI 0.51 to 0.57). Mean total costs of care were lower for those using palliative home care support (€3081 [95% CI €3025 to €3136] vs €4698 [95% CI €4610 to €4787]; incremental cost: -€1617 [p<0.001]).
Palliative home care support use positively impacts quality of care and reduces total costs of care at the end of life in Belgium. Policy makers and healthcare practitioners should increasingly focus on communicating the existing options for palliative home care support to patients and their caregivers.
评估姑息治疗家庭支持对生命最后 14 天内护理质量和成本的影响。
使用匹配的队列研究,通过链接行政数据库。
2012 年在比利时去世的所有人(n=107847)。
8837 名在生命最后 720 至 15 天内接受姑息治疗家庭支持的人,按倾向得分 1:1 匹配 8837 名接受常规护理的人。
接受姑息治疗家庭患者津贴、多学科姑息治疗家庭护理团队家访或姑息治疗护士或物理治疗师家访。
家庭死亡、家庭医生就诊次数、初级护理人员就诊次数、医院死亡、医院入院、重症监护病房(ICU)入院、急诊部(ED)入院、诊断性检查、输血和手术。所有结局均在生命的最后 14 天内进行测量。
在未匹配的队列中,11149 人(13.5%)在生命的最后 720 至 15 天内接受姑息治疗家庭支持。匹配后,使用姑息治疗家庭支持的人比未使用的人有更多的家庭医生就诊(平均 3.1[SD=6.5] vs 0.8[SD=1.2]),家庭死亡的可能性更大(56.2%vs13.8%;相对风险[RR]=4.08,95%CI 3.86 至 4.31),医院入院的风险较低(27.4%vs60.8%;RR=0.45,95%CI 0.43 至 0.46),ICU 入院(18.3%vs40.4%;RR=0.45,95%CI 0.43 至 0.48)或 ED 入院(15.2%vs28.1%;RR=0.54,95%CI 0.51 至 0.57)。使用姑息治疗家庭支持的人的总护理费用较低(€3081[95%CI €3025 至 €3136] vs €4698[95%CI €4610 至 €4787];增量成本:-€1617[<0.001])。
姑息治疗家庭支持的使用对生命最后阶段的护理质量产生积极影响,并降低了比利时的总护理成本。政策制定者和医疗保健从业者应更加关注向患者及其护理人员传达姑息治疗家庭支持的现有选择。